Australia Vaccine Market: Scaling Immunity Through Innovation and Local Production

Market Overview

• In 2024, the Australia vaccine market was valued at approximately USD 1,196 million.
• The market is forecast to reach USD 2,629.9 million by 2033, rising at a compound annual growth rate (CAGR) of around 9.15% from 2025 to 2033.
• Growth is being driven by several factors: rising public health awareness, increased prevalence of infectious diseases (influenza, RSV, etc.), national immunization programs, an aging population, preventive healthcare focus, technological innovation (including mRNA and recombinant vaccines), expanding cold chain infrastructure, and public-private R&D partnerships.

Key Trends & Market Drivers

Infectious Disease Burden & Seasonal Spikes

Australia has seen high influenza seasons and outbreaks of respiratory diseases. The increased cases of flu and other vaccine-preventable illnesses are pushing vaccine uptake in both public and private healthcare sectors.

Technological Innovation

Innovations such as mRNA vaccine platforms, recombinant and conjugate vaccines, adjuvants, and thermostable formulations are accelerating the development and rollout of more effective vaccines.

National Immunization Programs & Government Support

The National Immunization Program (NIP) in Australia provides free access to many vaccines (e.g. influenza, measles, pertussis, etc.). Such programs, along with centralized procurement, help ensure stable demand, higher coverage rates, and economies of scale.

Demographic Pressures & Adult Vaccination

With an aging population, there’s rising demand for adult and senior vaccines (e.g. influenza, pneumococcal, RSV). Also, increasing travel and awareness drive demand for travel-related vaccines.

Cold Chain & Distribution Infrastructure

Effective vaccine distribution depends on cold chain logistics, reach into remote areas, and well-trained healthcare delivery networks. Australia’s investment in these areas strengthens vaccine accessibility and reliability.

Get a PDF Request for a Free Sample Report: https://www.imarcgroup.com/australia-vaccine-market/requestsample

Opportunities in the Australia Vaccine Market

Local Manufacturing & Sovereign Production

The establishment of on-shore vaccine manufacturing—especially for mRNA-based vaccines—reduces reliance on imports, improves response time during outbreaks, and supports health security. Investments in local production capabilities are a major strategic opportunity.

R&D Investment for Advanced & Combination Vaccines

There is scope for developing combination vaccines (e.g. for influenza + RSV or other respiratory pathogens), better adjuvant technologies, and vaccines tailored for elderly immune systems. Supporting research in these areas can yield high returns.

Expanding Private Healthcare & Adult Vaccine Adoption

Beyond government-funded vaccines, there’s demand from private clinics, pharmacies, and high-income segments for optional vaccines—such as enhanced flu shots, travel vaccines, or newer vaccines like RSV. Private channel expansion could capture this market.

Strategic Partnerships & Public-Private Collaboration

Collaborations between biotech firms, governmental agencies, universities, and international partners can accelerate vaccine development, regulatory approval, and distribution.

Regulatory Approvals & Faster Variant-Matched Vaccines

Rapid approvals for updated vaccines (e.g. for new infectious disease variants) can give competitive advantage—especially for vaccine manufacturers that can pivot quickly.

Awareness & Preventive Healthcare Campaigns

Increased public education about adult vaccination, travel vaccination, and vaccine-preventable diseases can drive uptake. Campaigns targeting vulnerable populations (elderly, immunocompromised) are especially needed.

Recent News & Developments in the Australia Vaccine Market

December 2024 – First commercial-scale mRNA Vaccine Factory Opens in Melbourne

Australia inaugurated the Moderna Technology Centre – Melbourne, its first fully capable mRNA vaccine manufacturing facility. The facility is part of a USD 2+ billion, 10-year agreement with federal and state governments, and is set to produce the first COVID booster locally by winter 2025.

April 2024 – RSV Vaccine Approved for Adults Aged 60+

The Therapeutic Goods Administration (TGA) green-lit Arexvy, a vaccine against respiratory syncytial virus (RSV), for Australians aged 60 and over. This marks an expansion in vaccines targeting age-related respiratory illness beyond influenza.

September 2024 – New COVID-19 Vaccines for Emerging Variant JN.1 Under Review

Pfizer and Moderna submitted applications to Australia’s TGA for updated COVID-19 vaccines targeting the Omicron sub-variant JN.1. If approved, these are expected to be available around November 2024.

2025 – Approval of RSV mRESVIA® (mRNA-1345)

Moderna’s mRESVIA®, an mRNA-based vaccine for lower respiratory disease caused by RSV, has been approved in Australia for adults aged 60 and above. This is significant as it is among the newer vaccine technologies being cleared for use in non-COVID vaccine areas.

Recent Wildlife Vaccine Approval – Koala Chlamydia Vaccine

In September 2025, Australia approved its first vaccine for koalas to protect against chlamydia, which has impacted wild populations significantly. Though veterinary, this illustrates extension of vaccine R&D and regulatory processes beyond just human medicine.

Policy Moves & Regulatory Exemptions

Under a USD-2 billion deal initiated in previous years, Australia granted certain exemptions for Moderna's locally produced mRNA vaccines from some advisory committee reviews (PBAC), to speed up vaccine availability. There is debate about transparency in such routes.

Browse Full Report with TOC & List of Figures: https://www.imarcgroup.com/australia-vaccine-market

• The growth forecasts indicate that vaccines will be an increasingly central part of Australia’s healthcare spend—both for public health and private sectors. Stakeholders who align with technological innovation, rapid response to disease variants, and local manufacturing will be better positioned.
• Vaccines are critical in managing disease burden, reducing hospitalization costs, and protecting vulnerable populations like the elderly. With rising threats from infectious and zoonotic diseases, robust vaccine coverage is essential to health system resilience.
• For biotech firms, pharmaceutical companies, and public research institutions, this is a high-growth area ripe for investment: in R&D, production, deployment, and regulatory expertise.
• The move towards adult, travel, and variant-matched vaccines opens new markets beyond childhood immunization, broadening opportunities for private clinics, pharmacies, and supplementary health services.